<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7446744\results\search\testTrace\results.xml">
  <result pre="trials. Unfortunately, current trials are mostly examining these agents in" exact="isolation" post="and there may be a significant delay before evidence-based"/>
  <result pre="Immune dysregulation Thrombosis Key Summary Points Immune dysregulation in COVID-19" exact="infection" post="includes suppression of adaptive but hyperactivation of innate immune"/>
  <result pre="most effective in treating COVID-19 patients. Introduction A novel coronavirus" exact="infection" post="caused by the severe acute respiratory syndrome coronavirus 2"/>
  <result pre="organ failure [2]. The severe respiratory failure caused by COVID-19" exact="infection" post="results in acute hypoxemia, which is associated with severe"/>
  <result pre="interplay between hypercoagulability, thrombo-inflammation, and pulmonary microvascular thrombosis in COVID-19" exact="infection" post="resulting in respiratory failure and how this information can"/>
  <result pre="system. Not surprisingly, one of the major features of COVID-19" exact="infection" post="is involvement of the respiratory system. Importantly, ACE2 receptors"/>
  <result pre="[10]. While most patients will have symptoms of respiratory tract" exact="infection" post="and start to improve within a week, sudden clinical"/>
  <result pre="Immune Dysregulation in COVID-19 Infection Initial response to the viral" exact="infection" post="is by the activation of the innate immune system"/>
  <result pre="interferon response has been demonstrated in mice models of SARS-CoV" exact="infection" post="[22]. It is postulated that similar suppressed type 1"/>
  <result pre="(VEGF) concentrations on admission were higher in patients with COVID-19" exact="infection" post="compared to healthy adults [21]. In the same study,"/>
  <result pre="Respiratory Failure The pathophysiological mechanism of respiratory failure in COVID-19" exact="infection" post="is not clear at present but there is an"/>
  <result pre="is a direct consequence of vascular damage associated with viral" exact="infection" post="[45]. Antithrombotic Therapy in COVID-19 Because of the unusually"/>
  <result pre="Fibrin deposition can occur even before appearance of symptoms of" exact="infection" post="as identified in lung biopsy specimens of two patients"/>
  <result pre="for our understanding of the optimum anticoagulation strategy in this" exact="infection" post="to prevent thrombosis-associated complications. Table 1 Currently listed trials"/>
  <result pre="30, 2020) on clinicaltrial.gov with experimental anticoagulation intervention in COVID-19" exact="infection" post="Trial number Study title Location Intervention Primary aim Target"/>
  <result pre="Therapy Experience in COVID-19 Glucocorticoids have been investigated in the" exact="treatment" post="of COVID-19 disease. Unfortunately, the first randomized controlled trial"/>
  <result pre="increase the risk of severity and fatality of COVID 19" exact="infection" post="[59]. However, currently there is no definite evidence for"/>
  <result pre="well the systemic circulation. This understanding will help us develop" exact="treatment" post="protocols targeting various inflammatory pathways as well as to"/>
  <result pre="Hematol.202010.1007/s00277-020-04169-132656591 16.BoisramÃ©-HelmsJKremerHSchini-KerthVMezianiFEndothelial dysfunction in sepsisCurr Vasc Pharmacol201311215016023506494 17.VargaZFlammerAJSteigerPHabereckerMAndermattRZinkernagelASet al.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet202010.1016/S0140-6736(20)30937-532442527 18.ZuoYYalavarthiSShiHGockmanKZuoMMadisonJABlairCWeberABarnesBJEgebladMWoodsRJNeutrophil extracellular traps (NETs) as"/>
  <result pre="with lung cancerJ Thorac Oncol202015570070410.1016/j.jtho.2020.02.01032114094 51.WangJHajizadehNMooreEEMcIntyreRCMoorePKVeressLAet al.Tissue plasminogen activator (tPA)" exact="treatment" post="for COVID-19-associated acute respiratory distress syndrome (ARDS): a case"/>
  <result pre="review in rheumatoid arthritisDrugs201777171865187910.1007/s40265-017-0829-729094311 57.FuBXuXWeiHWhy tocilizumab could be an effective" exact="treatment" post="for severe COVID-19?J Transl Med202018116410.1186/s12967-020-02339-332290839 58.CaoWLiuXBaiTFanHHongKSongHet al.High-dose intravenous immunoglobulin"/>
  <result pre="antiviral and anti-inflammatory treatmentsLancet Infect Dis202020440040210.1016/S1473-3099(20)30132-832113509 62.RichardsonPGriffinITuckerCSmithDOechsleOPhelanAet al.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet202039510223e30e3110.1016/S0140-6736(20)30304-432032529 63.ZhangXJQinJJChengXShenLZhaoYCYuanYet al.In-hospital use of"/>
 </snippets>
</snippetsTree>
